Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 59
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more

Conditions: Macular Degeneration
Interventions: 0.5 mg ranibizumab; Drug
Lead sponsor: Charles C Wykoff, PhD, MD; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more

Conditions: Glabellar Frown Lines
Interventions: Botulinum toxin, Type A, 0.9% sterile, unpreserved saline; Biological · Other
Lead sponsor: Evolus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Non-adaptive Floreo VR control, Floreo Virtual Reality application; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 16 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: GW810781; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 17
States / cities: Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Prematurity
Interventions: Milking group, Immediate cord clamping; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide (SAR439977), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 4,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 79
States / cities: Sheffield, Alabama • Gilbert, Arizona • Surprise, Arizona + 69 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more

Conditions: Generalized Myasthenia Gravis
Interventions: Ravulizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more

Conditions: Smoking Cessation
Interventions: NicVAX Vaccine, Placebo Vaccine; Biological
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Encino, California • Los Alamitos, California • Denver, Colorado + 22 more

Conditions: Compare Ecchymosis and Edema for Fibrin Sealant and no Fibrin Sealant
Interventions: Fibrin Sealant (Artiss); Drug
Lead sponsor: Nguyen, Davis B., M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: 5% dextrose in water, TZP-101; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: San Francisco, California • Anderson, Indiana • Kansas City, Kansas + 3 more

Conditions: Post Operative Pain, Laparoscopic Sleeve Gastrectomy, Robotic Sleeve Gastrectomy, Obesity, Bariatric Surgery Candidate, Quality of Life
Interventions: Laparoscopic Sleeve Gastrectomy (LSG), Robotic Sleeve Gastrectomy (RSG); Procedure
Lead sponsor: Ricard Corcelles; Other
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non Small Cell Lung Cancer
Interventions: Surgeon's 'standard of care' stapler, Ethicon Powered Vascular Stapler; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obstructive Sleep Apnea
Interventions: Montelukast; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 2 Years to 10 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more

Conditions: Hepatitis B
Interventions: Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Bakersfield, California • San Francisco, California • Orlando, Florida + 4 more

Conditions: Multiple Myeloma, Renal Insufficiency
Interventions: BHQ880, BHQ880 Placebo, bortezomib, dexamethasone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Spokane, Washington

Conditions: Heart Failure, Congestive
Interventions: ENABLE CHF-PC; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Lebanon, New Hampshire

Conditions: Sunscreening Agents
Interventions: BAY987517, BullFrog Gel Sunscreen Land Sport SPF-50; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Placebo, JNJ-31001074; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 21
States / cities: Irvine, California • Lafayette, California • San Francisco, California + 18 more

Conditions: Overactive Bladder
Interventions: Tolterodine ER, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: San Francisco, California

Search by objective public record fields.

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Effect of Efpeglenatide on Cardiovascular Outcomes

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

Effects of Assisted Robotic vs Laparoscopic Sleeve Gastrectomy

Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies

Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

ENABLE: CHF-PC (Comprehensive Heartcare For Patients and Caregivers)

Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder